

References

I-207

1. Sun W, Liu H, Kim Y, Karras N, Pawlowska A, Toomey D, et al. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. *Journal of Hematology & Oncology*. 2018;11(61):1-5.
2. Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, et al. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34/CD123 cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors. *Haematologica*. 2018;103(8):1288-1297.
3. Elzonris™ (tagraxofusp-erzs) injection, for intravenous use [package insert]. Stemline Therapeutics, Inc. New York, NY. Revised 12/2018.
4. Leukemia & Lymphoma Society. Blastic Plasmacytoid Dendritic Cell Neoplasm. Available at: <https://www.lls.org/leukemia/blastic-plasmacytoid-dendritic-cell-neoplasm>. Accessed January 17, 2019.
5. Micromedex® Solutions Compendia. Tagraxofusp-erzs. 2020.
6. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Tagraxofusp-erzs. 2020.
7. Testa U, Pelosi E, Castelli G. CD123 as a therapeutic target in the treatment of hematological malignancies. *Cancers*. 2019;11(9):1358-1388.
8. Pemmaraju N, Lane A, Sweet K, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. *NEJM*. 2019;380:1628-1637.